What's new in the quagmire of sepsis?

Trends in Molecular Medicine

Volumn 20, Issue 4, 2014, Pages 189-190

  Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 7; TOLL LIKE RECEPTOR 4;

BACTERIAL TRANSLOCATION; BRAIN INJURY; CARDIOVASCULAR DISEASE; CLINICAL CLASSIFICATION; DIABETES MELLITUS; EDITORIAL; GENE EXPRESSION PROFILING; GRAM NEGATIVE INFECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; MOLECULAR MEDICINE; MULTIPLE ORGAN FAILURE; NATIONAL HEALTH ORGANIZATION; PHASE 3 CLINICAL TRIAL (TOPIC); SEPSIS; SEPTIC SHOCK; THERMAL INJURY;

ANIMALS; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL TRACT; HUMANS; IMMUNOLOGIC FACTORS; SEPSIS; TRANSCRIPTOME;

EID: 84897430465     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.02.003     Document Type: Editorial

References (6)

1. Ranieri V.M., et al. Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med. 2012, 366:2055-2064.
2. Opal S.M., et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013, 309:1154-1162.
3. Rice T.W., et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit. Care Med. 2010, 38:1685-1694.
4. Seok J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:3507-3512.
5. Hotchkiss R.S., et al. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 2013, 13:862-874.
6. Hirsiger S., et al. Danger signals activating the immune response after trauma. Mediators Inflamm. 2012, 2012. 315941, http://dx.doi.org/10.1155/2012/315941.